报价延迟最少15分钟:2025/09/02 08:19 EDT
盘前时段
|
||||
|
0.47 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.46/-0.32
|
|
企业价值
76.02M
|
| 资产负债 |
|
每股账面净值
0.12
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
455.00K
|
|
每股收益
0.07
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/02 08:19 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy. |
